HOME
Leading the way to a cure

Hobbled Johnson Helps ALR Take a Giant Leap

March 10, 2011

Woody Johnson might be having a little trouble walking around these days, but that hasn’t prevented him from keeping the Alliance for Lupus Research on the fast track for a cure to the autoimmune disease that can affect the joints and almost every major organ in the body.

Unable to attend an ALR fundraising event at the Atlantic Health Jets Training Center this week due to a fractured left ankle, the Jets Owner/ALR Chairman got a favorable prognosis from Mike Tannenbaum as we near the May 21 ALR Walk at the New Meadowlands Stadium.

“In the offseason we always have guys who need some surgery — some bigger than others and unfortunately Woody is on that list this year,” said the Jets GM.  “But we expect him to be full go for training camp and if he passes Rex’s conditioning run — he’ll be on the field as well.”

On Wednesday, US health officials announced approval of the first drug — Benlysta — in 56 years to treat lupus.

“As one of the pioneering funders and supporters of B-cell research, the Alliance for Lupus Research commends Human Genome Sciences and GlaxoSmithKline for their enduring commitment and tireless research efforts to bring belimumab (Benlysta) to people with lupus,” said ALR President Ken Farber.  “For everyone touched by this debilitating disease — people with lupus and their families, as well as lupus researchers around the world — we can today celebrate a major advance in treatment options for lupus.”

Johnson, who has a daughter with lupus, founded the ALR in 1999 and has been at the forefront of the organization that has raised more than $65 million to treat, cure and prevent lupus. Tannenbaum pointed out that more people suffer from this disease than leukemia, multiple sclerosis, cerebral palsy and cystic fibrosis combined and that of the 1.5 million Americans inflicted with it — an astounding 90 percent are women.

...

Read the full article here

Source newyorkjets.com

Share this page...